Pediatric Arginine Vasopressin Disorders (Diabetes Insipidus): Background, Pathophysiology, Etiology (original) (raw)

Overview

Background

Arginine vasopressin (AVP) deficiency (AVP-D) and AVP resistance (AVP-R) (formerly known as central or neurogenic diabetes insipidus and nephrogenic diabetes insipidus, respectively [1, 2] ) are part of a group of hereditary or acquired polyuria and polydipsia diseases in which the kidneys pass large amounts of water irrespective of the body's hydration state. AVP disorders are due either to (1) deficient secretion of antidiuretic hormone (ADH) by the pituitary gland (AVP-D) or to (2) renal tubular unresponsiveness to vasopressin (AVP-R).

The hallmarks of AVP-D are polyuria (urine volume in excess of 150 ml/kg/24 hr at birth, 100-110 ml/kg/24 hr until the age of 2 years, and 40-50 ml/kg/24 hr in older children and adults), dilute urine (osmolality < 300 mOsm/L), and polydipsia (water intake of up to 20 L/day). [3] AVP-R is characterized by polyuria with polydipsia, recurrent bouts of fever, constipation, and acute hypernatremic dehydration after birth that may cause neurologic sequelae.

Acquired AVP-D can occur at any age and is usually secondary to a condition damaging the central nervous system. Typical injuries include head trauma, tumor, and neurosurgical procedures. AVP-D is considered idiopathic in 20-50% of cases. [4]

AVP-D with an autosomal dominant pattern inheritance is due to a mutation in the prepro-arginine vasopressin (prepro-AVP2) gene, mapped to locus 20p13. AVP-D with diabetes mellitus, optic atrophy, and deafness (Wolfram syndrome) may be inherited in an autosomal recessive pattern (locus 4p16) or may be due to mitochondrial deletions. [2, 3, 5]

In up to 90% of cases, AVP-R is caused by mutations in the gene located on Xq28 coding for the V2 receptor of antidiuretic hormone (AVPR2). [6, 7, 8, 9] In cases of autosomal recessive or dominant transmission, AVP-R is caused by mutations in the AQP2 gene (located on chromosome 12) that codes for aquaporin-2. Aquaporin-2 is involved in the transportation of water in the renal tubules.

For AVP-D, the treatment of choice is the synthetic ADH analogue desmopressin (1-deamino-8-D-arginine vasopressin [DDAVP]). Other useful medications include chlorpropamide and thiazide diuretics. AVP-R cannot be effectively treated with desmopressin because the receptor sites are defective and the kidney is prevented from responding. Thiazide diuretics, amiloride, and indomethacin or aspirin are useful when coupled with a low-solute diet.

Pathophysiology

The basis of water loss in arginine vasopressin (AVP) disorders (eg, AVP deficiency [central diabetes insipidus], AVP resistance [nephrogenic diabetes insipidus], and syndrome of inappropriate secretion of antidiuretic hormone [SIADH]) is distinct from that of water loss caused by diabetes mellitus. The renal tubular collecting ducts are unable to concentrate urine secondary to ADH deficiency or resistance. [10]

The collecting duct concentrates urine by reabsorbing water, a function controlled by the posterior pituitary gland via secretion of AVP (ie, ADH). Reabsorption of sugars, amino acids, and virtually all electrolytes is completed by the time the urine has reached this segment of the nephron. Thus, the inability to conserve water by reabsorption in the collecting duct depletes body water but leaves sodium unaffected. The net result is an extremely diluted, increased urine output resulting in hypernatremia. Polydipsia follows, as the thirst mechanism urges replenishment of body water.

Secretion of ADH occurs in the posterior pituitary gland and is regulated at the paraventricular and supraoptic nuclei, which sense changes in osmolality. Destruction of the paraventricular or supraoptic nuclei or of the posterior pituitary by tumor, pressure, or surgical ablation results in decreased ADH secretion and AVP deficiency (AVP-D) . Alternatively, diabetes insipidus may be idiopathic or inherited as either an autosomal dominant or an autosomal recessive trait (locus 20p13).

AVP resistance (AVP-R) (nephrogenic diabetes insipidus) arises from defective or absent receptor sites at the cortical collecting duct segment of the nephron (X-linked, vasopressin V2 receptor deficiency, locus Xq28) or defective or absent aquaporin, the protein that transports water at the collecting duct (autosomal recessive, locus 12q13). [6, 11, 12] Eight mutations on AQP2 gene are associated with autosomal dominant AVP-R, and 32 mutations are associated with autosomal recessive AVP-R. [13] The X-linked variety of AVP-R accounts for about 90% of all such cases. It should be noted that the protein aquaporin-1 is a water channel expressed in the proximal tubule and in the thin descending limb of the loop of Henle and is not regulated by vasopressin. Although individuals with deficient aquaporin-1 have been shown to have impaired concentrating ability, under normal conditions such individuals are clinically unaffected. [14]

As a consequence of one of these defects, the ducts do not appropriately respond to ADH. Normally, ADH is transported in the blood to receptor sites on the basolateral surface of the collecting duct membrane. Through a G protein–adenylate cyclase coupling, activation of the ADH receptor increases cyclic adenosine monophosphate (cAMP) production and stimulates protein kinase A, leading to increased recycling of the protein aquaporin in the plasma membrane.

In the presence of ADH stimulus, exocytic insertion of aquaporin into the apical, or luminal, surface of the tubule cell occurs. Aquaporin enhances water entry into the cell from the lumen. Absence of the ADH receptor does not allow this process to take place, causing inhibition of water uptake and polyuria. Alternatively, defective or absent aquaporin impairs the process in the presence of normal V2 receptors. The subject of osmotic regulation has been reviewed by Danziger and Zeidel. [15]

Etiology

Arginine vasopressin (AVP) disorder (diabetes insipidus) is due either to (1) deficient secretion of ADH by the pituitary gland (arginine vasopressin deficiency [AVP-D]) (central diabetes insipidus) or to (2) renal tubular unresponsiveness to vasopressin (AVP resistance [AVP-R]) (nephrogenic diabetes insipidus). Both genetic and nongenetic causes are known. [16, 17]

Nongenetic causes

Nongenetic causes of AVP disorder include injuries and illness, with typical ones including head trauma, tumor, and neurosurgical procedures. At all ages, destructive lesions of the pituitary, the hypothalamus, or both are the most common cause of AVP disorder. AVP-D is considered idiopathic in 20-50% of cases. [4] However, two studies have found a higher prevalence of CNS malformations in patients with AVP-D than previously reported, as well as fewer idiopathic cases. [18, 19] Although a causal relationship has not been proven, COVID-19 has been implicated in the pathogenesis of AVP-D. [20]

Werny and colleagues reported that children diagnosed with idiopathic AVP-D with findings of stalk thickening on the initial MRI were more likely to have an underlying diagnosis (40% vs 0%; P = 0.03). In the study, of 147 patients with AVP-D (mean age 7 yr at diagnosis, mean follow-up 6.2 yr), the most common single diagnosis was craniopharyngioma (25.2%), followed by septo-optic dysplasia (14.3%), and Langerhans cell histiocytosis (LCH) (12.2%). Idiopathic AVP-D was the diagnosis in 12.2% of cases. [19]

Genetic causes

X-linked AVP-R occurs from mutations in the antidiuretic arginine vasopressin V2 receptor (AVPR2) gene, mapped to Xq28. [6, 7, 8] In cases of autosomal recessive or dominant transmission, AVP-R is caused by mutations in the AQP2 gene (located on chromosome 12) that codes for aquaporin-2. Aquaporin-2 is involved in the transportation of water in the renal tubules.

Epidemiology

Arginine vasopressin (AVP) disorder (diabetes insipidus) is a rare disease, with an overall prevalence of 1:25,000. [21] Tumors, infiltrative lesions, malformations, and neurosurgical procedures are the most common causes of AVP disorders. Less than 10% of AVP disorder is hereditary. X-linked AVP resistance (AVP-R) (nephrogenic diabetes insipidus) accounts for 90% of cases of congenital AVP-R and occurs with a frequency of 4 to 8 cases per 1 million male births. Autosomal AVP-R accounts for approximately 10% of cases. Of the genetic etiologies, the overall incidence in the general population is estimated to be 3 cases per 100,000 population (0.003%). [4]

In a large Danish study in 2014, the annual incidence of AVP deficiency (AVP-D) (central diabetes insipidus) overall was 3 to 4 patients per 100,000, with an incidence of 2 cases of congenital AVP-D per 100,000 infants. [22]

AVP disorder occurs across a wide age range. Idiopathic AVP deficiency (AVP-D) onset can occur at any age but is most often seen in 10- to 20-year-olds. [3] Children who present with autosomal recessive AVP-D are generally younger than 1 year; those who present with autosomal dominant AVP-D are often older than 1 year. AVP-R (including X-linked, autosomal dominant, and autosomal recessive forms) develops in early infancy, often in neonates younger than 1 week.

AVP-D secondary to hypothalamic-pituitary lesions occurs at random and should, therefore, be evenly distributed between the sexes. Autosomal dominant and autosomal recessive AVP-D occur equally in both sexes. AVP-R caused by an X-linked mutation affects only males. Autosomal dominant and autosomal recessive forms of AVP-R equally affect both sexes.

Prognosis

Long-term survival in cases of arginine vasopressin deficiency (AVP-D) (central diabetes insipidus) depends on the precipitating cause. In primary AVP-D, the prognosis is excellent with early recognition and appropriate desmopressin therapy. However, AVP-D in the acute phase after traumatic brain injury is associated with hypernatremia and increased intracranial pressure and high mortality rates of 33-82%. [23]

The earlier onset of AVP resistance (AVP-R) (nephrogenic diabetes insipidus) and the reduced ability to treat this variety of the disease render the child more prone to attention deficit, hyperactivity, learning disorders, and psychomotor delay. As long as water remains available at all times to replace the massive losses, long-term survival is not in question.

Complications

Complications include the following:

Growth failure
Nocturia and enuresis
Hypernatremic dehydration
Seizures
Intellectual disability

Dehydration results from an inability to reabsorb free water at a site distal to electrolyte reabsorption. Any patient unable to continuously replace water loss is vulnerable to dehydration, especially in warm weather when insensible water loss through perspiration and respiration substantially increases risk.

Electrolyte abnormalities are caused by the loss of urinary free water, which produces hyperosmolar dehydration, leading to hypernatremia, hyperchloremia, and prerenal azotemia. Diminished blood volume increases blood viscosity and the risk of sludging and thrombosis.

Failure to thrive occurs because of the patient’s constant thirst conferring a sense of fullness that offsets the sense of hunger. The affected individual eats less than necessary for normal growth.

Seizures are a consequence of the electrolyte abnormalities introduced in the central nervous system (CNS) by severe hypernatremia and hyperosmolar dehydration. Intellectual disability results from the damage to the CNS caused by severe hyperosmolarity, seizures, and potential hypoxia, all of which are thought to account for the frequent occurrence of intellectual disability. Death can occur from a hypovolemic shock or a hypernatremic seizure.

Patient Education

Parents must be educated regarding water replacement in infants and young children who cannot express thirst or access fluids without assistance. Gastrointestinal illnesses that cause decreased intake, increased stool losses, or both must receive early and serious attention to prevent life-threatening electrolyte and fluid balance abnormalities. (See the videos below.)

Pediatric Arginine Vasopressin Disorders (Diabetes Insipidus). Diabetes Sick Day Rules.

Pediatric Arginine Vasopressin Disorders (Diabetes Insipidus). Taking Diabetes Back to School.

Arima H, Cheetham T, Christ-Crain M, et al, for the Working Group for Renaming Diabetes Insipidus. Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus. Endocr J. 2022 Nov 28. 69(11):1281-4. [QxMD MEDLINE Link]. [Full Text].
Serbis A, Rallis D, Giapros V, Galli-Tsinopoulou A, Siomou E. Wolfram syndrome 1: a pediatrician's and pediatric endocrinologist's perspective. Int J Mol Sci. 2023 Feb 12. 24(4):3690. [QxMD MEDLINE Link]. [Full Text].
Central diabetes insipidus. Orphannet. Available at https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=17999&Disease_Disease_Search_diseaseGroup=diabetes-insipidus&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Central-diabetes-insipidus&title=Central-diabetes-in. July 2012; Accessed: September 15, 2017.
Di Iorgi N, Allegri AE, Napoli F, et al. Central diabetes insipidus in children and young adults: etiological diagnosis and long-term outcome of idiopathic cases. J Clin Endocrinol Metab. 2014 Apr. 99(4):1264-72. [QxMD MEDLINE Link]. [Full Text].
Rutishauser J, Spiess M, Kopp P. Genetic forms of neurohypophyseal diabetes insipidus. Best Pract Res Clin Endocrinol Metab. 2016 Mar. 30(2):249-62. [QxMD MEDLINE Link].
Knepper MK, Kwon T, Nielsen S. Molecular physiology of water balance. New Engl J Med. 2015 April 2. 372;14:1349-58. [QxMD MEDLINE Link].
Wildin RS, Antush MJ, Bennett RL. Heterogeneous AVPR2 gene mutations in congenital nephrogenic diabetes insipidus. Am J Hum Genet. 1994 Aug. 55(2):266-77. [QxMD MEDLINE Link].
Faerch M, Christensen JH, Corydon TJ, et al. Partial nephrogenic diabetes insipidus caused by a novel mutation in the AVPR2 gene. Clin Endocrinol (Oxf). 2008 Mar. 68(3):395-403. [QxMD MEDLINE Link].
Bichet DG, Bockenhauer D. Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant). Best Pract Res Clin Endocrinol Metab. 2016 Mar. 30(2):263-76. [QxMD MEDLINE Link].
Driano JE, Lteif AN, Creo AL. Vasopressin-dependent disorders: What is new in children?. Pediatrics. 2021 May. 147(5):e2020022848. [QxMD MEDLINE Link]. [Full Text].
Mulders SM, Bichet DG, Rijss JP, et al. An aquaporin-2 water channel mutant which causes autosomal dominant nephrogenic diabetes insipidus is retained in the Golgi complex. J Clin Invest. 1998 Jul 1. 102(1):57-66. [QxMD MEDLINE Link]. [Full Text].
Milano S, Carmosino M, Gerbino A, Svelto M, Procino G. Hereditary nephrogenic diabetes insipidus: pathophysiology and possible treatment. An update. Int J Mol Sci. 2017 Nov 10. 18(11):2385. [QxMD MEDLINE Link]. [Full Text].
Chandrasekaran K, Karolina DS, Sepramaniam S, et al. Role of microRNAs in kidney homeostasis and disease. Kidney Int. 2012 Apr. 81(7):617-27. [QxMD MEDLINE Link]. [Full Text].
Agre P, King LS, Yasui M, et al. Aquaporin water channels - from atomic structure to clinical medicine. J Physiol. 2002. 542:3-16. [QxMD MEDLINE Link].
Danziger J, Zeidel ML. Osmotic homeostasis. Clin J Am Soc Nephrol. 2015. 10:852-862. [QxMD MEDLINE Link].
Davies JH, Penney M, Abbes AP, et al. Clinical features, diagnosis and molecular studies of familial central diabetes insipidus. Horm Res. 2005. 64(5):231-7. [QxMD MEDLINE Link].
Garofeanu CG, Weir M, Rosas-Arellano MP, Henson G, Garg AX, Clark WF. Causes of reversible nephrogenic diabetes insipidus: a systematic review. Am J Kidney Dis. 2005 Apr. 45(4):626-37. [QxMD MEDLINE Link].
Hunter JD, Calikoglu AS. Etiological and clinical characteristics of central diabetes insipidus in children: a single center experience. Int J Pediatr Endocrinol. 2016. 2016:3. [QxMD MEDLINE Link]. [Full Text].
Werny D, Elfers C, Perez FA, Pihoker C, Roth CL. Pediatric central diabetes insipidus: brain malformations are common and few patients have idiopathic disease. J Clin Endocrinol Metab. 2015 Aug. 100(8):3074-80. [QxMD MEDLINE Link]. [Full Text].
Capatina C, Poiana C, Fleseriu M. Pituitary and SARS CoV-2: an unremitting conundrum. Best Pract Res Clin Endocrinol Metab. 2023 Jul. 37(4):101752. [QxMD MEDLINE Link]. [Full Text].
Christ-Crain M, Bichet DG, Fenske WK, et al. Diabetes insipidus. Nat Rev Dis Primers. 2019 Aug 8. 5(1):54. [QxMD MEDLINE Link].
Juul KV, Schroeder M, Rittig S, Norgaard JP. National surveillance of central diabetes insipidus (CDI) in Denmark: results from 5 years registration of 9309 prescriptions of desmopressin to 1285 CDI patients. J Clin Endocrinol Metab. 2014 Jun. 99(6):2181-7. [QxMD MEDLINE Link].
Hannon MJ, Crowley RK, Behan LA, et al. Acute glucocorticoid deficiency and diabetes insipidus are common after acute traumatic brain injury and predict mortality. J Clin Endocrinol Metab. 2013 Aug. 98(8):3229-37. [QxMD MEDLINE Link]. [Full Text].
Timper K, Fenske W, Kuhn F, et al. Diagnostic accuracy of copeptin in the differential diagnosis of the polyuria-polydipsia syndrome: a prospective multicenter study. J Clin Endocrinol Metab. 2015 Jun. 100(6):2268-74. [QxMD MEDLINE Link]. [Full Text].
Urano F. Wolfram syndrome: diagnosis, management, and treatment. Curr Diab Rep. 2016 Jan. 16(1):6. [QxMD MEDLINE Link]. [Full Text].
Winzeler B, Zweifel C, Nigro N, et al. Postoperative copeptin concentration predicts diabetes insipidus after pituitary surgery. J Clin Endocrinol Metab. 2015 Jun. 100(6):2275-82. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Expert Panel on Neurologic Imaging: Burns J, Policeni B, Bykowski J, et al. ACR Appropriateness Criteria(®) Neuroendocrine Imaging. J Am Coll Radiol. 2019 May. 16(5S):S161-S173. [QxMD MEDLINE Link]. [Full Text].
Boussemart T, Nsota J, Martin-Coignard D, Champion G. Nephrogenic diabetes insipidus: treat with caution. Pediatr Nephrol. 2009 Sep. 24(9):1761-3. [QxMD MEDLINE Link].
D'Alessandri-Silva C, Carpenter M, Mahan JD. Treatment regimens by pediatric nephrologists in children with congenital nephrogenic diabetes insipidus: A MWPNC study. Clin Nephrol. 2018 May. 89(5):358-63. [QxMD MEDLINE Link].
Al Nofal A, Lteif A. Thiazide diuretics in the management of young children with central diabetes insipidus. J Pediatr. 2015 Sep. 167(3):658-61. [QxMD MEDLINE Link].
Alon U, Chan JC. Hydrochlorothiazide-amiloride in the treatment of congenital nephrogenic diabetes insipidus. Am J Nephrol. 1985. 5(1):9-13. [QxMD MEDLINE Link].
Saborio P, Tipton GA, Chan JC. Diabetes insipidus. Pediatr Rev. 2000 Apr. 21(4):122-9; quiz 129. [QxMD MEDLINE Link].
Smego AR, Backeljauw P, Gutmark-Little I. Buccally administered intranasal desmopressin acetate for the treatment of neurogenic diabetes insipidus in infancy. J Clin Endocrinol Metab. 2016 May. 101(5):2084-8. [QxMD MEDLINE Link]. [Full Text].
Mavinkurve M, McGrath N, Johnston N, Moloney S, Murphy NP, Hawkes CP. Oral administration of diluted nasal desmopressin in managing neonatal central diabetes insipidus. J Pediatr Endocrinol Metab. 2017 May 24. 30(6):623-8. [QxMD MEDLINE Link].

Pediatric Arginine Vasopressin Disorders (Diabetes Insipidus). Carbs for Kids-Count Them In: The Constant Carbohydrates Diet.
Pediatric Arginine Vasopressin Disorders (Diabetes Insipidus). Diabetes Sick Day Rules.
Pediatric Arginine Vasopressin Disorders (Diabetes Insipidus). Taking Diabetes Back to School.

Author

Karl S Roth, MD Retired Professor and Chair, Department of Pediatrics, Creighton University School of Medicine

Karl S Roth, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American College of Nutrition, American Pediatric Society, American Society for Nutrition, American Society of Nephrology, Association of American Medical Colleges, Medical Society of Virginia, New York Academy of Sciences, Sigma Xi, The Scientific Research Honor Society, Society for Pediatric Research, Southern Society for Pediatric Research